CG Oncology (CGON) closed at $74.40 on November 13, 2026, up 6.1% from the previous close, on volume of 2,705,164 shares (30-day average 998,962).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 4, 2026 | Call with Delta Hedge | 20-Nov-26 75 C +250,000 Stock | 6,250 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates
Globe Newswire (Fri, 6-Nov 8:15 AM ET)
Globe Newswire (Tue, 13-Oct 8:00 AM ET)
Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm
PRNewswire (Mon, 12-Oct 9:32 PM ET)
CG Oncology to Present at Upcoming Investor Conferences in September
Globe Newswire (Wed, 2-Sep 8:00 AM ET)
CG Oncology Bolsters Cash Position to $1.1 Billion While Advancing Multiple Clinical Milestones
Market Chameleon (Fri, 8-May 5:24 AM ET)
Market Chameleon (Fri, 9-Jan 5:30 AM ET)
Market Chameleon (Fri, 9-Jan 4:39 AM ET)
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
CG Oncology trades on the NASDAQ stock market under the symbol CGON.
As of November 13, 2026, CGON stock price climbed to $74.40 with 2,705,164 million shares trading.
CGON has a beta of 0.39, meaning it tends to be less sensitive to market movements. CGON has a correlation of 0.01 to the broad based SPY ETF.
CGON has a market cap of $6.65 billion. This is considered a Mid Cap stock.
Last quarter CG Oncology reported $2 million in Revenue and -$.64 earnings per share. This beat revenue expectation by $960,416 and exceeded earnings estimates by $.18.
The top ETF exchange traded funds that CGON belongs to (by Net Assets): VTI, IWM, VB, XBI, VBK.
CGON has outperformed the market in the last year with a price return of +97.0% while the SPY ETF gained +13.4%. CGON has also outperformed the stock market ETF in the last 3 month and 2 week periods returning -0.4% and +15.0%, respectively, while the SPY returned -2.8% and -0.2%, respectively.
CGON support price is $67.74 and resistance is $72.56 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CGON shares will trade within this expected range on the day.
